Successfully Concluded | BIgFish Showcases at the 2026 Dubai International Laboratory Equipment Exhibition

Integrated “Instrument + Reagent” Solutions Attract Attention

Addressing the core needs of the Middle Eastern IVD market, BIgFish highlighted four core testing instruments and supporting reagent kits, forming an integrated “instrument + reagent” molecular diagnostic solution. This comprehensive approach became one of the highlights of the exhibition, attracting many visitors to stop by the booth for consultation and in-depth discussions.

The showcased reagent kits include nucleic acid extraction reagents and HBV lyophilized nucleic acid detection reagents, among other product categories. These reagents are precisely matched with the exhibited instruments, enabling a complete testing workflow and providing customers with a one-stop molecular diagnostic solution that meets diverse application scenarios in the Middle East, including clinical diagnostics, scientific research, and primary healthcare.

Four Core Instruments Cover the Entire Testing Workflow

During the exhibition, BIgFish presented four core testing instruments:

• BFEX-32E Fully Automatic Nucleic Acid Extraction and Purification System

• BFQP-1650 Fluorescence Quantitative Analyzer

• FC-96B Gene Amplification Instrument

• BFDB-N1 Metal Bath

Working together, these instruments cover the entire workflow from nucleic acid extraction, amplification, detection, to sample preprocessing, meeting testing requirements across multiple application scenarios.

The BFEX-32E Fully Automatic Nucleic Acid Extraction and Purification System, as the core extraction device, offers convenient operation and stable performance without requiring complex site deployment. Using optimized magnetic bead extraction technology combined with BIgFish’s self-developed nucleic acid extraction reagents, it can flexibly process multiple sample types and quickly complete efficient nucleic acid capture and purification. The system also includes a disinfection filtration function that effectively prevents cross-contamination, lowers operational complexity, and improves testing efficiency and safety.

The BFQP-1650 Fluorescence Quantitative Analyzer focuses on portability and ease of deployment, allowing flexible use without a professional laboratory environment. Equipped with intelligent analysis software supporting both Chinese and English interfaces, it enables simple operation, rapid nucleic acid amplification, and result interpretation. When used together with HBV lyophilized nucleic acid detection reagents, it effectively supports clinical diagnostic applications.

The FC-96B Gene Amplification Instrument offers both high efficiency and excellent cost performance. Its compact design and efficient heat dissipation ensure stable operation. With an intuitive interface, even beginners can quickly get started. Compatible with multiple consumable formats, it is widely used in research and clinical scenarios such as genetic testing and pathogen screening.

The BFDB-N1 Metal Bath, serving as a key auxiliary device for sample preprocessing, features stable temperature control and efficient heat conduction. With easy operation and multiple interchangeable modules compatible with different consumables, it supports various experimental procedures including nucleic acid pre-denaturation, enzymatic reactions, sample thawing, and constant-temperature incubation. When used together with nucleic acid extraction reagents, it further optimizes the sample preprocessing workflow.

In addition to magnetic bead nucleic acid extraction reagents compatible with the BFEX-32E, the supporting reagent kits exhibited at the event also include HBV lyophilized nucleic acid detection reagents, addressing core clinical testing needs in the Middle East. Together with the four core instruments, these products form a comprehensive molecular diagnostic solution covering the entire testing process.

Debuting in Dubai, Expanding Globally

As a national high-tech enterprise deeply engaged in molecular diagnostics, BIgFish continuously focuses on the core needs of the molecular diagnostics field. The company has invested heavily in instrument hardware and software development, reagent R&D, and product iteration. Leveraging multiple independent patented technologies, BIgFish has developed intelligent, cost-effective testing products and solutions covering nucleic acid extraction, quantitative PCR systems, and a full range of molecular diagnostic instruments, along with supporting nucleic acid extraction reagents and infectious disease nucleic acid detection reagents, forming an integrated “instrument + reagent” ecosystem.

Several BIgFish testing instruments and reagent products have already been widely used in clinical diagnostics, scientific research, and food safety applications, gaining strong market recognition. Participation in WHX Labs Dubai 2026 represents an important step for BIgFish in expanding international markets and strengthening global brand influence, while also showcasing the global reach of China’s in vitro diagnostic technologies.

During the exhibition, BIgFish attracted strong interest through its high-quality products and professional technical presentations, reaching preliminary cooperation intentions with multiple testing institutions, distributors, and research organizations from the Middle East and around the world. As one of the fastest-growing regions in the global medical device market, the Middle East offers enormous potential. This exhibition not only demonstrated BIgFish’s technological innovation achievements but also provided valuable market feedback and partnership opportunities.

Looking ahead, BIgFish will continue to listen to market needs, optimize its products and solutions, deepen international cooperation, and contribute to the improvement of molecular diagnostics and public health services in the Middle East. By strengthening the integration of Chinese molecular diagnostic technologies with the global market, BIgFish aims to contribute to the advancement of global healthcare.